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Abstract
Background: There is limited data on the effect of HIV status and CD4 counts on performance of Interferon-g
Release assays (IGRAs) for diagnosis of latent tuberculosis infection (LTBI).
Methods: A cross sectional study was conducted to assess the prevalence of and risk factors for a positive
diagnostic test for LTBI, using tuberculin skin test (TST) and IGRAs among HIV-discordant couples in Zambia.
Results: A total of 596 subjects (298 couples) were enrolled. Median CD4 count among HIV positive persons was
388 cells/μl, (range 51-1330). HIV negative persons were more likely than their HIV positive partner, to have a
positive diagnostic test for LTBI with TST (203 vs 128), QFT (171 vs 109) and TSPOT (156 vs. 109). On multivariate
analysis, HIV negative status was an independent predictor for a positive QFT (OR = 2.22, 95% CI 1.42- 3.46) and
TSPOT (OR = 1.79, 95% CI 1.16-2.77). Among HIV positive subjects a CD4 count ≥ 388 cells/μl was associated with a
positive TST (OR = 1.76 95% CI 1.10-2.82) and QFT (OR = 1.71 95% CI 1.06-2.77) but not TSPOT (OR = 1.20 95% CI
0.74-1.94).
Conclusions: Persons with HIV had significantly fewer positive diagnostic tests for LTBI with TST, QFT and TSPOT.
Persons with a CD4 count < 388 cells/μl were less likely to have a positive TST or QFT, but not less likely to have a
positive TSPOT. TSPOT may perform better than TST or QFT in HIV positive individuals.
Background
HIV and tuberculosis (TB) are the leading causes of death
among adults due to an infectious disease worldwide. It is
estimated that > 13 million people are co-infected with
HIV and Mycobacterium tuberculosis [1]. The World
Health Organization (WHO) estimates that there are
approximately 9.3 million new cases of active TB and
nearly 2 million deaths due to the disease worldwide each
year [2,3]. Twenty-seven percent of TB cases and 31% of
TB-related deaths occur in Africa, home to only 11% of
the world’s population [4].
HIV infection is the most important risk factor for pro-
gression from latent tuberculosis infection (LTBI) to
active TB [5,6]. In patients with HIV and LTBI, the
annual risk of progression to active TB is approximately
10% per year [7-9] compared to a lifetime risk of 5-10%
in immunocompetent persons [7]. Diagnosis and treat-
ment of LTBI is a major strategy for TB control and pre-
vention in the US [7,10]. WHO has recommended the
implementation of isoniazid preventive therapy for HIV-
seropositive persons in an effort to prevent additional
cases of TB, but this strategy has not yet been widely
adopted in Africa [3].
For nearly a century, diagnosis of LTBI has relied on the
tuberculin skin test (TST) which has several limitations
including low specificity due to cross reaction with BCG
vaccination and non-tuberculous mycobacteria (NTM)
and low sensitivity in HIV infection. New diagnostic tests
for tuberculosis are urgently needed to enhance global TB
control [11,12].
Two Interferon-g release assays (IGRAs) are now
commercially available for the diagnosis of LTBI
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T-SPOT.TB [TSPOT]) [13,14]. IGRAs provide increased
specificity over TST, because the antigens used in the
test do not cross react with BCG or other NTM. How-
ever, there is limited data on whether these tests provide
any benefit over TST in immunocompromised indivi-
duals, such as those with HIV, particularly in high pre-
valence countries [14-21].
We conducted an observational cohort study to assess
t h ep e r f o r m a n c eo ft h r e ed i a g n o s t i ct e s t sf o rL T B I
(TST, QFT and TSPOT) in HIV positive persons and
compared these results to the results of their HIV nega-
tive partner (control group), in Zambia. The goals of
our study were: 1. To assess prevalence of a positive test
for latent tuberculosis infection; 2. To assess concor-
dance between TST, QFT and IGRAs; 3. To determine
whether HIV is a risk factor for a positive test with
TST, QFT or TSPOT; 4. Among HIV positive indivi-
duals to determine if CD4 count is an independent pre-
dictor for a positive TST, QFT or TSPOT.
Methods
The study was conducted in Lusaka at the Zambia Emory
HIV Research Project (ZEHRP). ZEHRP consists of a
cohort of heterosexual HIV discordant couples and pro-
motes couple’s voluntary counseling and testing (CVCT)
as a method of HIV prevention and as an entry-point
into HIV clinical care [22]. Recruitment and study proce-
dures have been described elsewhere [23-27].
HIV-infected individuals (> 16 years of age) and their
discordant (HIV-seronegative) partner were offered an
opportunity to enroll in the study. Exclusion criteria
included pregnancy, active TB, or if the couple failed to
come to the clinic appointment together. The study was
approved by the Emory University Institutional Review
Board (IRB) and the University of Zambia Research
Ethics Committee and study subjects provided written
informed consent.
Each study subject had two study visits. At the first
study visit, study subjects were asked to complete a ques-
tionnaire that included questions regarding exposure to
TB at home, history of BCG vaccination and history of
incarceration. Blood was drawn from study participants
for IGRA tests (3 ml for the QFT test [Cellestis Inc,
Australia] test and 8 ml for the TSPOT [Oxford Immuno-
tec, Oxford, UK]). HIV infected persons had a CD4 count
performed. Following the blood draw, a TST was placed
using 0.1 ml of PPD reagent (Tubersol, Sanofi Pasteur) by
the Mantoux method [6]. Study participants were
instructed to return in 48 to 72 hours to have the TST
read. The amount of induration (in mm) was recorded by
a trained health care provider. Based on national and
international guidelines, a positive TST was defined as ≥
5 mm of induration in HIV-infected persons and ≥ 10 mm
in HIV-seronegative persons [7]. Persons with a positive
TST had a chest radiograph performed and were ques-
tioned about symptoms in order to exclude active TB
disease.
The QFT and TSPOT tests were performed based on
the manufacturer’s instructions and as previously
reported [12-14,16]. Interferon-g release was measured
using ELISA after stimulation of sensitized T-cells using
TB specific antigens. The test was considered positive if
the interferon-g response to TB antigens minus the
negative control was ≥ 0.35 IU/ml and > 25% of the
negative control; negative if these criteria were not met;
and indeterminate if either the negative control had a
result of ≥ 8I U / m l ,o ri ft h ep o s i t i v ec o n t r o lh a da
result of < 0.5 IU/ml of interferon-g.
For TSPOT 250,000 peripheral blood mononuclear cells
(PBMCs) were isolated and plated per well. Each test con-
sisted of four wells: a negative control, a positive control
(PHA) and TB specific antigens (CFP10 and ESAT 6).
Spot forming units were counted manually and using an
EliSpot Reader, (Cellular Technology Ltd., Cleveland, OH).
A positive TSPOT test was defined as a response to either
ESAT6 or CFP10 minus the negative control that is ≥ 8
spot forming cells and > 2 times the negative control; the
test was negative if these criteria were not met; and the
test was indeterminate if the reading in the negative con-
trol was > 20 spots or if the reading in the positive control
were < 20 spots. All reported TSPOT results are based on
results from the ELISPOT Reader.
Sample size and statistical analysis
Sample size calculation was performed using prevalence
of LTBI in Zambia from a previous study [28]. The pre-
cision method was used, by estimating the half width of
the 95% confidence intervals we calculated a sample size
of 300 couples.
Data analysis was performed using SAS 9.1 (SAS Inc,
Cary, NC). Outcomes of interest included prevalence of
LTBI, concordance between diagnostic tests, and risk fac-
tors associated with a positive test result. Concordance
between the diagnostic tests for LTBI (IGRAs and TST)
was measured using -statistic [13]. Risk factors for diag-
nostic test positivity were evaluated using odds ratios and
95% confidence interval. Variables that were analyzed
included age, gender, HIV status, CD4 count, household
income, exposure to a household member with TB within
the last one month, history of incarceration and history
of BCG vaccination. Initially univariate analysis was per-
formed to assess risk factors for a positive test. Because
of the matched study design a conditional logistic regres-
sion was performed to determine if HIV was a risk factor
for a positive TST, QFT and TSPOT when comparing
each HIV positive person to their HIV negative partner.
Variables included in the final model were those that
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plausibility, were confounders or effect modifiers. A sub-
set analysis was then performed on only the HIV positive
persons using unconditional logistic regression to mea-
sure the association between CD4 count and a positive
test result. Age and CD4 count were converted to catego-
rical variables. Median values were used to convert con-
tinuous variables to categorical variables. We defined a
p-value of < 0.05 as being statistically significant.
Results
Out of a cohort of 546 HIV-discordant couples cur-
rently enrolled at ZEHRP 403 couples met the prescre-
ening criteria for study enrollment. The cross section
for this study consists of 298 discordant couples or 596
study subjects (Figure 1). The median age of study parti-
cipants was 33 years (range 17-59 years), median
monthly income was the equivalent of US $32 (range
US $ 0-1908). Women were significantly more likely to
be HIV positive than men (60% vs 40%, p < 0.0001).
Median CD4 count among HIV positive persons was
388 cells/μl, (range 51-1330 cells/μl). None of the study
subjects were on antiretroviral therapy.
Demographic and clinical data for study subjects is
summarized in Table 1.
Diagnostic Test Results
Tuberculin Skin Test (TST)
A total of 331 (55.5%) persons had a positive TST, 252
(42.3%) had a negative TST, and 13 (2.2%) did not
return to have their TST read. The median TST reading
for persons with HIV was 18 mm and for persons with-
out HIV was 16.5 mm (p-value = 0.05).
QuantiFERON-TB Gold in Tube (QFT) Test
280 (47.0%) persons had a positive QFT, 281 (47.2%) had
a negative QFT and 35 (5.8%) had an indeterminate test.
Among persons with a positive QFT, persons without
HIV secreted a higher level of Interferon g 3.5 IU/ml in
comparison to people who had HIV 1.8 IU/ml (p-value =
0.0001).
TSPOT.TB (TSPOT) Test
A total of 265 (44.5%) had a positive TSPOT, 313 (52.5%)
had a negative test, and 18 (3.1%) had an indeterminate
result. Among persons with a positive TSPOT, HIV posi-
tive individuals exhibited 44.2 spots/ml and HIV negative
persons had 53 spots/ml (p-value = 0.3).
HIV positive persons were significantly less likely to
have a positive TST, QFT or TSPOT result (Table 2).
Indeterminate Test results with IGRAs
All 18 indeterminate TSPOT results occurred due to tech-
nical errors resulting in a high value in the negative con-
trol well. Five of the 35 indeterminate test results with the
QFT occurred because of inadequate interferon-g release
in response to the positive control. All five of these cases
occurred among HIV positive individuals and the median
CD4 count was 264 cells/μl.
Test results stratified by CD4 counts
Among HIV -seropositive individuals, subjects with a CD4
count < 388 cells/μl were less likely to have a positive test
with TST and QFT, when compared to subjects with CD4
count ≥ 388 cells/μl. This difference was not seen with
TSPOT (Figure 2).
Concordance Between Diagnostic Tests for Latent TB
Infection
Concordance between TST and QFT, TST and TSPOT
and QFT and TSPOT was measured among HIV positive
and HIV negative individuals. Overall concordance was
moderate and there was no difference when comparing
concordance between HIV positive and HIV negative
subjects. (Table 3). For the TSPOT test, concordance
between readings with a magnifying lens verses an ELI-
SPOT reader was moderate  = 0.67 (95% CI 0.61-0.73).
Risk factors for a positive diagnostic test for LTBI
Univariate analysis was performed and HIV negative status
was found to be a risk factor for a positive test for TST
(OR = 2.87, 95% CI = 1.94-3.97), QFT (OR = 2.18 95%
CI = 1.48-2.99) and TSPOT (OR = 1.97 95% CI = 1.26-
2.53). In addition males were more likely to have a positive
TST (OR = 1.97 95% CI 1.39-2.79) and TSPOT (OR =
1.80 95% CI 1.27-2.55), however this effect was only seen
on univariate analysis. BCG vaccination, household con-
t a c tw i t hac a s eo fa c t i v eT B ,h i s t o r yo fp r i s o ns t a ya n d
income were not found to be risk factors for a positive test
with TST, QFT or TSPOT. On multivariate analysis sub-
jects who were HIV negative were more likely to have a
positive TST, QFT and TSPOT, when controlling for age
and gender. (Table 4) We found interaction between age
and HIV in the multivariate model for tuberculin skin test.
Among persons who are HIV negative, subjects who were
< 32 years have an OR for a positive TST of 1.86; subjects
who were > 32 years have an OR for a positive TST of
3.67.
We then performed multivariate analysis on HIV posi-
tive individuals alone and found that subjects with a
CD4 count ≥ 388 cells/μlw e r em o r el i k e l yt oh a v ea
positive TST (OR 1.76 95% CI 1.10-2.82) or QFT (OR
1.71, 95% CI 1.06-2.77). This association was not seen
with TSPOT (OR1.20, 95% CI 0.74-1.94).
Discussion
This is the first study to investigate all three diagnostic
tests for latent tuberculosis infection (TST, QFT and
TSPOT) in an HIV positive population and to compare
results to an HIV negative partner as a control group.
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2 had active TB
37 presented 
without partner        15 pregnant 
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87 couples had 
no study visit 
Figure 1 Enrollment of Study Subjects from ZEHRP Cohort.
Table 1 Clinical characteristics of HIV positive and HIV negative subjects enrolled in the study (n = 596)
Characteristics of study subjects HIV positive
n = 298
HIV negative
n = 298
p-value
Age median and range 32 (18-59 years) 34 (17-59 years) 0.045
Male Gender 118 (40%) 180 (60%) < 0.0001
History of prior incarceration 16 (5%) 18 (6%) 0.7
History of BCG vaccination 223(75%) 220 (74%) 0.9
History of household TB exposure in past 30 days 33 (11%) 37(12%) 0.8
Median monthy income $ 32 32 0.6
Median CD4 count 388 cells/μl
BCG: Bacillus Calmette-Guérin
HIV: Human Immunodeficiency Virus
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study subjects with similar demographic, socioeconomic
and exposure data to determine what the effect of HIV
is on LTBI test positivity. The TST has been shown to
have decreased sensitivity among HIV positive persons
but there have been limited data on the sensitivity of
IGRAs in this population [29-31]. Since one of the stra-
tegies to control tuberculosis is diagnosis and treatment
of LTBI particularly among HIV-infected persons, we
sought to assess IGRAs for the diagnosis LTBI among
HIV-infected persons.
The prevalence of a positive test with TST, QFT and
TSPOT was significantly lower among HIV positive per-
sons, when compared to HIV negative persons, suggesting
these tests do not perform as well in HIV positive persons.
Induration with TST was greater in HIV negative than in
HIV positive persons and amount of interferon-gamma
release with QFT was greater among HIV negative per-
sons than HIV positive persons. There was no difference
in spot forming cells for TSPOT between HIV positive
and HIV negative persons. TST and QFT produced more
positive test results in HIV positive and negative indivi-
duals than TSPOT but this was not statistically significant.
On multivariate analysis being HIV negative was the
only predictor for a positive test result, with TST, QFT
and TSPOT, while controlling for other risk factors.
A study from Africa compared QFT in HIV positive and
negative subjects within the same population and was
unable to show a difference in rates of test positivity
based on HIV status. However that study had a small
sample size and the HIV negative (controls) were not as
closely matched as in our study [18]. A study from
Spain did show that rates of positive QFT were lower
among HIV positive than HIV negative individuals but
TSPOT was not evaluated [32].
We performed multivariate analysis to assess whether
CD4 count was an independent predictor of TST, QFT
or TSPOT positivity. Among HIV-seropositive persons,
aC D 4c o u n t≥ 388 cells/μl was associated with a posi-
tive TST and QFT. CD4 count was not a predictor for a
positive test result with TSPOT. This finding suggests
that TSPOT may work better than TST or QFT among
HIV positive individuals as results are not dependant on
ap a t i e n t ’s CD4 count. A study from Uganda also found
that the rate of positive TSPOT results were comparable
in HIV positive patients with CD4 counts < 100, 100-
250 and > 250 cells/μl, however no multivariate analysis
was performed in this study [33].
We compared concordance between TST and IGRAs,
a n db e t w e e nQ F Ta n dT S P O Ta n df o u n df a i rc o n c o r -
dance. There was no difference in concordance when we
looked at just HIV-seropositive persons, or only HIV
negative persons. Several other studies have shown fair to
poor concordance in HIV [19-21]. Since concordance
depends on prevalence, values from developed countries
are lower than those from high incidence developing
countries and are difficult to compare [14-18].
Most studies in HIV positive individuals have shown a
large number of indeterminate results and these have
been associated with low CD4 counts [16,17]. Our study
had a low incidence of indeterminate test results and
most of these occurred due to a high interferon reading
in the negative control well, a finding that occurs due to
technical problems. Five cases of indeterminate QFT
results occurred due to inadequate interferon in the posi-
tive control. All of these occurred in HIV positive indivi-
duals. We had fewer indeterminate test results with
TSPOT than with QFT.
Our study has several limitations. The median CD4
count in our population was high (388 cells/μl) and no
study subject was on HAART. It is difficult to assess how
these tests would perform at lower CD4 counts. Our
study used the HIV negative partner as a control, to esti-
mate the baseline prevalence of latent tuberculosis in the
study population. We realize that both partners within a
couple would not have identical exposures to tuberculo-
sis, and that this may be considered a shortcoming of our
study. However we do feel that their exposures would be
similar and therefore both groups should have a similar
rate of LTBI. Future studies could ask for more detailed
Table 2 Prevalence of a positive diagnostic test for
Latent Tuberculosis Infection (LTBI) stratified by HIV
status (n = 596)
Diagnostic Test for LTBI HIV positive
n = 298
HIV negative
n = 298
p-value
TST 128 (43%) 203 (69%) 0.0003
QFT 109 (37%) 171 (58%) 0.006
TSPOT 109 (37%) 156 (53%) 0.005
TST: Tuberculin Skin Test.
QFT: QuantiFERON-TB Gold In Tube Test.
TSPOT: TSPOT.TB Test.
HIV: Human Immunodeficiency Virus.
  p-value  =0.02   p-value=0.02   p-value=0.46 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
TST QFT TSPOT
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37%
44%
   32%
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35%
Figure 2 Positive diagnostic test for latent tuberculosis
infection stratified by CD4 count (n = 298).
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and therefore we don’t have longitudinal data to deter-
mine whether a positive IGRA predicts future risk of
active TB. However longitudinal studies are not practical
d u et ot h en e e df o ral a r g es a m p l es i z ea n df o l l o wu p
over several years.
The advantage of conducting a study in a high inci-
dence country is that we have a large number of positive
IGRA test results and therefore have more power for
analysis of risk factors. In addition, we used a unique
study design where we matched each HIV positive per-
son to their HIV negative domestic partner and then
carried out a matched analysis using unconditional
logistic regression. This is the first study to show that
TSPOT may have an advantage over TST and QFT for
diagnosis of LTBI among HIV positive persons.
Conclusions
In conclusion, our study suggests that HIV positive status
does decrease the sensitivity of TST, QFT and TSPOT.
On multivariate analysis HIV status was the only predic-
tor of test positivity for TST, QFT and TSPOT. Among
HIV positive subjects a CD4 count > 388 cells/μlw a s
associated with a positive TST and QFT, but not TSPOT.
Based on the findings of our study it appears that
TSPOT may be a better diagnostic test for LTBI in HIV
positive persons, as results do not depend on CD4 count.
Further research to evaluate use of TSPOT at lower CD4
counts and in other immunocompromised states is
needed.
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Table 3 Concordance between the three diagnostic tests described in all subjects, HIV seropositive subjects and HIV
seronegative subjects
Test in HIV positive subjects (n = 298) Agreement (%)  95% Confidence Interval
TST vs QFT 75% 0.53 0.43, 0.64
TST vs TSPOT 76% 0.4 0.3, 0.52
TSPOT vs QFT 74% 0.37 0.26, 0.49
Test in HIV negative subjects (n = 298) Agreement (%)  95% Confidence Interval
TST vs QFT 72% 0.44 0.33, 0.55
TST vs TSPOT 70% 0.3 0.2, 0.4
TSPOT vs QFT 75% 0.46 0.35, 0.57
TST: Tuberculin Skin Test.
QFT: Quantiferon-TB Gold In Tube Test.
TSPOT: TSPOT.TB Test.
HIV: Human Immunodeficiency Virus.
Table 4 Multivariate Analysis, using Conditional Logistic
Regression to evaluate Risk Factors for a Positive
Diagnostic Test for Latent Tuberculosis Infection
Risk factors for positive
TST
Odds Ratio 95% Confidence
Interval
Age < 32 years 0.98 0.36-2.62
Male Gender 1.33 0.79-2.22
HIV negative*
Age < 32 years
Age ≥ 32 years
1.86
3.67
1.06-2.67
1.60-8.39
Risk factors for positive
QFT
Odds Ratio 95% Confidence
Interval
Age < 32 years 0.56 0.24-1.36
Male Gender 0.92 0.55-1.53
HIV negative 2.22 1.42-3.46
Risk factors for positive
TSPOT
Prevalence
Ratio
95% Confidence
Interval
Age < 32 years 0.98 0.42-2.28
Male Gender 1.59 0.92-2.76
HIV negative 1.79 1.16-2.77
*Interaction between age and HIV.
TST: Tuberculin Skin Test.
QFT: Quantiferon-TB Gold In Tube Test.
TSPOT: TSPOT.TB Test.
HIV: Human Immunodeficiency Virus.
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